State of Play
We are experiencing a “golden twenties” in science with breakthrough therapies in rare diseases, oncology, cell and gene therapy, and regenerative medicine, but…
-
Biotech and Big Pharma will bring a record number of NCEs and biologics to market
-
Precision-medicine at the core
-
Drug development model essentially unchanged since 1960ies intro of RCTs and evidence-based medicine
-
Prices for new drugs keep going up
-
Combined budget impact will put pressure on government and private payers
Opportunity to re-purpose and improve established therapies with novel drug design and delivery systems
-
Improve established therapies with novel drug design and delivery systems
-
Re-purpose known drugs based on new science; design new patentable molecules and delivery systems
Opportunity to transform drug development leveraging digital solutions
-
Established biopharma is conservative and without incentives to cut development costs
-
Many tech companies, incl start-ups, have individually novel digital solutions but fail to evolve into a decentralised ecosystem
-
Patient-centricity still not at the centre of the biopharma development model
Corporate Philosophy
Health Minister to Pharma CEO: “You need to be disrupted”
Conversation among Finance Ministers at OECD meeting: “We need Uberification of pharma”
Our beliefs
-
Alongside Big Pharma delivering from the frontiers of science, there is a need for a complementary model
-
The drug development model will not be changed through Schumpeter-like creative destruction; it has to change from within
-
Transformation of drug development can only take place taking forward real assets (molecules), not through wholesale A-Z transformation platforms or programs
-
By making drug development go faster and at lower cost, we can help make drugs more affordable
Our plan
-
Using re-purposing and novel drug design and delivery systems to obtain patented assets
-
Assembling a decentralised ecosystem of big and small entrepreneurs to digitally transform the drug development model through virtual clinical trials and patient engagement through the whole life cycle
-
Keep assets together to leverage platform and ecosystem while seeking development funding from different biopharma and VCs, with different funding models.
End To End Orchestration
With Multi-disciplinary
“Dream Team”
Driving Virtual
Drug Development


Early Patient Engagement,
re-purposing, unmet needs

Novel Drug design and
drug delivery

Formulation, delivery
mechanism

Virtual & decentralized
clinical trials

Patient reported outcomes,
digital tools for HCPs

Engage with pharmacies and emerging retailers